Charles Schwab’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $161M | Sell |
297,162
-3,319
| -1% | -$1.87M | 0.02% | 547 |
|
|
2026
Q1 | $178M | Buy |
300,481
+10,555
| +4% | +$5.26M | 0.03% | 465 |
|
|
2025
Q4 | $141M | Sell |
289,926
-23,022
| -7% | -$10.7M | 0.02% | 554 |
|
|
2025
Q3 | $131M | Sell |
312,948
-22,937
| -7% | -$7.71M | 0.02% | 578 |
|
|
2025
Q2 | $96.5M | Sell |
335,885
-14,973
| -4% | -$4.47M | 0.02% | 692 |
|
|
2025
Q1 | $108M | Sell |
350,858
-19,682
| -5% | -$6.75M | 0.02% | 621 |
|
|
2024
Q4 | $131M | Buy |
370,540
+585
| +0.2% | +$215K | 0.02% | 534 |
|
|
2024
Q3 | $133M | Sell |
369,955
-17,838
| -5% | -$6.03M | 0.03% | 522 |
|
|
2024
Q2 | $124M | Sell |
387,793
-10,644
| -3% | -$2.82M | 0.02% | 543 |
|
|
2024
Q1 | $91.5M | Buy |
398,437
+79,407
| +25% | +$17.9M | 0.02% | 642 |
|
|
2023
Q4 | $70.2M | Buy |
319,030
+7,723
| +2% | +$1.78M | 0.02% | 751 |
|
|
2023
Q3 | $70.3M | Sell |
311,307
-22,048
| -7% | -$5.08M | 0.02% | 682 |
|
|
2023
Q2 | $73.6M | Buy |
333,355
+19,326
| +6% | +$4.28M | 0.02% | 638 |
|
|
2023
Q1 | $70.3M | Buy |
314,029
+2,433
| +0.8% | +$600K | 0.02% | 629 |
|
|
2022
Q4 | $86.7M | Buy |
311,596
+12,207
| +4% | +$3.08M | 0.03% | 535 |
|
|
2022
Q3 | $62.7M | Sell |
299,389
-99,104
| -25% | -$22.2M | 0.02% | 631 |
|
|
2022
Q2 | $93.9M | Buy |
398,493
+6,666
| +2% | +$1.36M | 0.03% | 470 |
|
|
2022
Q1 | $70.3M | Buy |
391,827
+13,184
| +3% | +$2.51M | 0.02% | 673 |
|
|
2021
Q4 | $81.8M | Buy |
378,643
+5,358
| +1% | +$1.05M | 0.02% | 623 |
|
|
2021
Q3 | $68.9M | Buy |
373,285
+1,933
| +0.5% | +$381K | 0.02% | 676 |
|
|
2021
Q2 | $66.6M | Buy |
371,352
+4,544
| +1% | +$865K | 0.02% | 683 |
|
|
2021
Q1 | $61.4M | Buy |
366,808
+16,208
| +5% | +$2.7M | 0.02% | 701 |
|
|
2020
Q4 | $53.2M | Buy |
350,600
+7,817
| +2% | +$1.03M | 0.02% | 738 |
|
|
2020
Q3 | $34.6M | Sell |
342,783
-2,001
| -0.6% | -$220K | 0.02% | 867 |
|
|
2020
Q2 | $41.7M | Buy |
344,784
+9,400
| +3% | +$1.06M | 0.02% | 699 |
|
|
2020
Q1 | $31.8M | Buy |
335,384
+8,947
| +3% | +$850K | 0.02% | 714 |
|
|
2019
Q4 | $28.8M | Buy |
326,437
+9,907
| +3% | +$872K | 0.02% | 963 |
|
|
2019
Q3 | $25.2M | Buy |
316,530
+92,047
| +41% | +$7.41M | 0.01% | 991 |
|
|
2019
Q2 | $17.5M | Buy |
224,483
+8,366
| +4% | +$782K | 0.01% | 1232 |
|
|
2019
Q1 | $25.4M | Buy |
216,117
+15,713
| +8% | +$1.83M | 0.02% | 965 |
|
|
2018
Q4 | $21.8M | Buy |
200,404
+11,501
| +6% | +$1.33M | 0.02% | 944 |
|
|
2018
Q3 | $24.2M | Buy |
188,903
+9,786
| +5% | +$1.21M | 0.02% | 1023 |
|
|
2018
Q2 | $20.3M | Buy |
179,117
+11,726
| +7% | +$1.29M | 0.01% | 1064 |
|
|
2018
Q1 | $18.8M | Buy |
167,391
+9,120
| +6% | +$1.16M | 0.01% | 1047 |
|
|
2017
Q4 | $23.4M | Buy |
158,271
+8,243
| +5% | +$1.05M | 0.02% | 879 |
|
|
2017
Q3 | $17.6M | Buy |
150,028
+6,304
| +4% | +$805K | 0.02% | 1024 |
|
|
2017
Q2 | $18.6M | Sell |
143,724
-25,088
| -15% | -$3.13M | 0.02% | 900 |
|
|
2017
Q1 | $22.9M | Buy |
168,812
+24,209
| +17% | +$3.67M | 0.02% | 741 |
|
|
2016
Q4 | $20.7M | Buy |
144,603
+16,472
| +13% | +$2.1M | 0.02% | 741 |
|
|
2016
Q3 | $15.1M | Buy |
128,131
+4,886
| +4% | +$587K | 0.02% | 876 |
|
|
2016
Q2 | $13.1M | Buy |
123,245
+9,033
| +8% | +$1.01M | 0.02% | 893 |
|
|
2016
Q1 | $12.7M | Sell |
114,212
-5,097
| -4% | -$645K | 0.02% | 884 |
|
|
2015
Q4 | $18.7M | Buy |
119,309
+17,732
| +17% | +$2.58M | 0.03% | 628 |
|
|
2015
Q3 | $13.3M | Sell |
101,577
-30,064
| -23% | -$4.82M | 0.02% | 789 |
|
|
2015
Q2 | $22.9M | Buy |
131,641
+7,934
| +6% | +$1.43M | 0.03% | 518 |
|
|
2015
Q1 | $21.3M | Buy |
123,707
+14,369
| +13% | +$2.19M | 0.03% | 530 |
|
|
2014
Q4 | $14.2M | Sell |
109,338
-44,464
| -29% | -$5.73M | 0.02% | 668 |
|
|
2014
Q3 | $19.8M | Sell |
153,802
-102,392
| -40% | -$10.6M | 0.03% | 496 |
|
|
2014
Q2 | $22.7M | Buy |
256,194
+84,218
| +49% | +$8.1M | 0.04% | 445 |
|
|
2014
Q1 | $16.2M | Buy |
171,976
+7,686
| +5% | +$786K | 0.03% | 540 |
|
|
2013
Q4 | $18.6M | Buy |
164,290
+82,810
| +102% | +$7.47M | 0.04% | 450 |
|
|
2013
Q3 | $6.71M | Sell |
81,480
-78,038
| -49% | -$5.7M | 0.01% | 929 |
|
|
2013
Q2 | $10.8M | Buy |
+159,518
| New | +$10.3M | 0.02% | 546 |
|
Other funds holding UTHR
ACA
JT
Charles Schwab's UTHR Position: Q2 2026 in Review
Charles Schwab reduced its United Therapeutics (UTHR) stake by 1.1% in Q2 2026, selling an estimated $1.87M and leaving 297,162 shares worth $161M. The position accounts for 0.02% of the portfolio, ranked #547.
Charles Schwab first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $178M in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.
- Charles Schwab held 297,162 shares of United Therapeutics worth $161M as of Q2 2026.
- Charles Schwab sold 3,319 United Therapeutics shares in Q2 2026, an estimated $1.87M.
- United Therapeutics made up 0.02% of Charles Schwab's portfolio in Q2 2026, its #547 holding.
- Charles Schwab first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's United Therapeutics position peaked at $178M in Q1 2026.
- 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.